Technical Analysis for CADL - Candel Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Up 4 Days in a Row | Strength | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 1.61% | |
| Volume Surge | Other | 1.61% | |
| Wide Bands | Range Expansion | 1.61% | |
| Up 3 Days in a Row | Strength | 1.61% | |
| Oversold Stochastic | Weakness | 1.61% | |
| Slingshot Bearish | Bearish Swing Setup | 6.96% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 5 hours ago |
| Rose Above Previous Day's High | about 5 hours ago |
| Rose Above 10 DMA | about 5 hours ago |
| Down 5% | about 5 hours ago |
| Down 3% | about 5 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/09/2024
Candel Therapeutics, Inc. Description
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of cancer immunotherapy drugs. The company offers Gene Mediated Cytotoxic Immunotherapy technology-based drugs that are designed to work with radiation, chemotherapy, and surgery to eradicate residual tumor cells that could lead to recurrence or metastases. Its product candidates include CAN-2409, an off-the-shelf adenovirus product candidate, for the treatment of localized, primary prostate cancer and therapy for pancreatic cancer; and CAN-3110, its HSV product candidate, has been engineered for enhanced specificity and tumor cell killing, while minimizing toxicity on healthy tissue and indicated for the treatment of recurrent high-grade glioma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was founded in 1999 and is based in Needham, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Drugs Immunotherapy Surgery Tumor Cancer Immunotherapy Chemotherapy Radiation Pancreatic Cancer Metastases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 14.3 |
| 52 Week Low | 0.66 |
| Average Volume | 871,266 |
| 200-Day Moving Average | 3.22 |
| 50-Day Moving Average | 8.16 |
| 20-Day Moving Average | 6.88 |
| 10-Day Moving Average | 6.19 |
| Average True Range | 0.77 |
| RSI (14) | 41.18 |
| ADX | 26.14 |
| +DI | 19.18 |
| -DI | 25.82 |
| Chandelier Exit (Long, 3 ATRs) | 7.06 |
| Chandelier Exit (Short, 3 ATRs) | 7.82 |
| Upper Bollinger Bands | 8.52 |
| Lower Bollinger Band | 5.24 |
| Percent B (%b) | 0.32 |
| BandWidth | 47.67 |
| MACD Line | -0.67 |
| MACD Signal Line | -0.61 |
| MACD Histogram | -0.0636 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 7.46 | ||||
| Resistance 3 (R3) | 7.43 | 7.03 | 7.26 | ||
| Resistance 2 (R2) | 7.03 | 6.73 | 7.04 | 7.20 | |
| Resistance 1 (R1) | 6.66 | 6.55 | 6.85 | 6.69 | 7.13 |
| Pivot Point | 6.26 | 6.26 | 6.35 | 6.27 | 6.26 |
| Support 1 (S1) | 5.89 | 5.96 | 6.08 | 5.92 | 5.47 |
| Support 2 (S2) | 5.49 | 5.78 | 5.50 | 5.40 | |
| Support 3 (S3) | 5.12 | 5.49 | 5.34 | ||
| Support 4 (S4) | 5.15 |
